Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
IMB Dx, Inc.
About
  2. Companies
  3. IMB Dx, Inc.
  4. Products
  5. AlphaLiquid - Tumor-Agnostic Test

AlphaLiquid - Tumor-Agnostic Test

SHARE

Tissue specimens are either from surgical resections or biopsies which may raise the risk of bleeding, and infection and further require recovery from the procedure. Genomic profiling of tissue samples provides a single point in space and time which is lacking the ability to reveal tumor heterogeneity and to test repeatedly to monitor the treatment efficacy. The risk of tissue biopsy is much higher for elderly patients and patients who are taking blood thinners. And the amount of specimen from one biopsy is not sufficient when several single driver gene tests are done separately (e.g. EGFR, ALK, ROS1, BRAF etc.).

Most popular related searches
liquid biopsy sample
tissue biopsy
whole blood
genomic profile
genomic profiling
clinical analysis
surgical resection
tissue specimen
tumor dna
tumor response

AlphaLiquid® profiling test leverages liquid biopsy samples to detect tumor cell-derived circulation tumor DNA(ctDNA) that circulates in the bloodstream. A minimally invasive simple blood draw can avoid the inconvenience of surgical biopsy and detect ctDNA from bloodstream to overcome the heterogeneity in metastatic tumors which is not available for tissue biopsy in most cases.

AlphaLiquid®100 test is a CGP(Comprehensive Genomic Profiling, CGP) test detects variants across 118 cancer-related genes. The AlphaLiquid®100 is applicable for all solid tumors, including the leading cancer types like lung, gastric, colon, breast prostate, and also available for rare tumors including melanoma, sarcoma etc.

  • Assay Type: Targeted hybrid capture NGS based on proprietary
  • HQS™ technology
  • Sample Requirement: 20mL of whole blood (cfDNA input amount: 5-30ng)
  • Panel Size: 466kb
  • No. of genes: 118 genes (including 15 HRR genes)
  • Detected Alterations (5): SNVs, Indels, CNAs, Fusions, HRR
  • Detected Signatures: MSI, TMB

*HRR (Homologous recombination repair) genes: genes involved in repair of damaged DNA

Minimum of 10mL of patient`s whole blood is collected, stored and shipped in a tube that stabilizes cfDNA (eg., Streck tube), which are then sent to IMBdx`s central laboratory for analysis

cfDNA is isolated from blood and undergoes Quality Control (QC). QC-passed samples are then prepared into NGS libraries through an automated proprietary process, after which high-throughput NGS is performed.

Various genetic alternations (SNVs, Indels, CNAs, Fusions, HRR) and signatures (MSI, TMB, LOH) are analyzed from the NGS data using IMBdx`s patented, machine-learning enabled bioinformatics pipeline.

A clinical analysis report is generated and sent to the treating physician, providing information including detected variants and matching guideline-recommended therapy options, longitudinal tumor response analytics, as well as relevant on-going clinical trials.